HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
about
HIV broadly neutralizing antibody targetsHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titersSpatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection.Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination.Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Mechanisms of central tolerance for B cells.Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS.The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?
P2860
Q27026662-C57C0FDB-92DD-47C7-9CAE-DF56782F2FC2Q30234773-4F2D8AD8-5928-4E1F-91A2-7D85AE2A2735Q30391094-4E8D6F55-DD4D-4024-A5B0-E63717471471Q30490942-18C308F9-6915-495F-BEBA-E70B18507AA3Q35640984-311BC23F-EC40-411E-A0E1-F55DC122696AQ35925331-0B3CC72B-DA80-4CE1-A191-F72D831C042DQ35960908-8FCF5443-94FE-4205-AF7F-2BC1DAD2A295Q38702368-9E0B3AFB-C080-4783-8D57-8DCF00E4976FQ38954558-1468A728-372C-4D14-B4CC-BFABED3406DAQ39108735-A6FD3C4B-BF62-4277-9A59-A4428DCB82A2Q39214736-124B8BA5-86DE-49C1-85F2-048FC76C7601Q41925820-F8876A6E-2B53-4CB1-9FE6-97F6B52011CEQ47547492-FEDB7740-FC9B-413F-BD48-0478FEA4F7A3Q52581587-FD42434D-DBD4-4563-920E-5060CBCCE00EQ55000969-D447DA25-4E86-4AC2-BAFC-56CBF346675B
P2860
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@ast
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@en
type
label
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@ast
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@en
prefLabel
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@ast
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@en
P2860
P1433
P1476
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
@en
P2093
Laurent Verkoczy
P2860
P304
P356
10.1371/JOURNAL.PPAT.1004073
P577
2014-05-22T00:00:00Z